WHO Unveils Innovative TB Testing Guidelines to Accelerate Global Fight Against Tuberculosis
On World TB Day, the World Health Organization (WHO) issued new guidelines for tuberculosis (TB) testing, introducing innovations such as near-point-of-care molecular diagnostic tests and simplified sample collection methods. These measures aim to improve detection efficiency, reduce costs, and accelerate treatment initiation for a disease that causes over 3,300 deaths daily globally.
Context of Tuberculosis
Tuberculosis, a bacterial disease primarily affecting the lungs, accounts for over 3,300 deaths daily worldwide, with nearly 40 percent of these fatalities occurring in Southeast Asia. The disease is both preventable and treatable, including with antibiotics such as rifampicin. Global efforts against TB have reportedly prevented an estimated 83 million deaths since 2000.
New Diagnostic Guidelines and Innovations
The World Health Organization has issued new guidelines endorsing advanced diagnostic tests and simplified sample collection methods to expand access to services.
New Diagnostic Tools
- Near-Point-of-Care Molecular Diagnostic Tests: These portable, user-friendly tests aim to bring TB diagnosis closer to patients.
- They are available at less than half the cost of many current molecular diagnostics.
- They can operate on battery power and provide results within one hour, potentially enabling earlier treatment initiation.
- These devices are also capable of testing for other diseases, including HIV, mpox, and HPV.
Expanded Sample Collection Methods
- Tongue Swabs: This method allows adults and adolescents who are unable to produce sputum to be tested for TB, facilitating detection among individuals at increased risk.
- Sputum Pooling Strategy: This involves combining samples from multiple individuals for testing, which can reduce commodity costs and machine time. This approach aims to provide faster results for both patients and TB programs, particularly in resource-limited settings.
WHO Director-General Tedros Adhanom Ghebreyesus stated that these new tools could facilitate faster, accurate diagnosis closer to people, potentially saving lives, curbing transmission, and reducing costs.
Global Challenges and Funding Needs
Despite past progress, the WHO notes that current funding reductions are jeopardizing achievements in TB control. Challenges in the adoption of rapid diagnostic tools in many countries have included high costs and reliance on centralized laboratories, which require sample transport.
Ending TB requires sustained investment in research and innovation. Current global funding for TB research is reported to be significantly below the estimated annual need of approximately US$5 billion. The WHO is collaborating with partners, including through the TB Vaccine Accelerator Council, to expedite the development and equitable distribution of new TB vaccines.
WHO's Urgent Call to Action
On World TB Day, observed under the theme 'Yes! We can end TB,' the WHO called for urgent actions from governments and partners to:
- Accelerate the implementation of point-of-care diagnostic technologies and other innovations.
- Strengthen patient-centered TB care with community leadership.
- Build resilient health systems to ensure health security.
- Address the social and economic factors contributing to TB through multisectoral action.
- Protect essential TB services amidst global crises and financial constraints.
Dr. Tereza Kasaeva, Director of WHO’s Department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections, indicated that every dollar invested in combating TB generates up to US$43 in health and economic returns. She also stated the necessity of leadership, strategic investment, and rapid implementation of WHO recommendations and innovations.
The organization encourages governments and partners to prioritize TB as a cornerstone of health security and universal health coverage.